Estrogen use, APOE, and cognitive decline
- 23 May 2000
- journal article
- Published by Wolters Kluwer Health in Neurology
- Vol. 54 (10) , 1949-1954
- https://doi.org/10.1212/wnl.54.10.1949
Abstract
Objective: APOE-ε4 increases the risk of cognitive decline, while elderly women who take estrogen may have less risk of cognitive decline. The authors sought to determine whether estrogen use modifies the association between APOE-ε4 and cognitive decline. Method:— As part of the Cardiovascular Health Study, 3,393 Medicare-eligible women (≥65 years) were randomly selected and recruited from Sacramento County, CA; Washington County, MD; Forsyth County, NC; and Pittsburgh, PA. Cognitive testing was administered annually; the authors studied the 2,716 women with cognitive testing on ≥2 visits. They analyzed change in score on the Modified Mini-Mental State Examination (3MS) as a function of estrogen use, APOE genotype, and baseline common and internal carotid artery wall thickening. Results: A total of 297 (11%) women were current estrogen users and 336 (12%) were past estrogen users. Over the 6-year average follow-up, baseline current users declined 1.5 points on the 3MS whereas never users declined 2.7 points (p = 0.023). Compared with ε4-negative women, ε4-positive women had a greater adjusted hazard ratio of cognitive impairment (3MS < 80), hazard risk [HR] = 1.47; 95% CI, 1.13 to 1.90. There was an interaction between estrogen use and ε4 presence (p = 0.037). Among ε4-negative women, current estrogen use reduced the risk of adjusted cognitive impairment compared with never users by almost half (HR = 0.59; 95% CI, 0.36 to 0.99), whereas, it did not reduce the risk among ε4-positive women (current use, HR = 1.33; 95% CI, 0.74 to 2.42). Compared with never use, current estrogen use was associated with less internal and common carotid wall thickening in ε4-negative women but not in ε4-positive women (p for interaction < 0.05 for both). Differences remained after adjusting for age, education, race, and stroke. Conclusions: Estrogen use was associated with less cognitive decline among ε4-negative women but not ε4-positive women. Potential mechanisms, including carotid atherosclerosis, by which ε4 may interact with estrogen and cognition warrant further investigation.Keywords
This publication has 31 references indexed in Scilit:
- Estrogen Up-regulates Apolipoprotein E (ApoE) Gene Expression by Increasing ApoE mRNA in the Translating Pool via the Estrogen Receptor α-Mediated PathwayJournal of Biological Chemistry, 1997
- Apolipoprotein E Polymorphism Is Associated With Segment-Specific Extracranial Carotid Artery Intima-Media ThickeningStroke, 1996
- Current estrogen-progestin and estrogen replacement therapy in elderly women: Association with carotid atherosclerosisAnnals of Epidemiology, 1996
- Apolipoprotein E genotyping in the differential diagnosis, not prediction, of Alzheimer's diseaseAnnals of Neurology, 1995
- Apolipoprotein E polymorphism and Alzheimer's diseaseThe Lancet, 1993
- Pulsatility index in internal carotid artery in relation to transdermal oestradiol and time since menopauseThe Lancet, 1991
- Use of sonography to evaluate carotid atherosclerosis in the elderly. The Cardiovascular Health Study. CHS Collaborative Research Group.Stroke, 1991
- The cardiovascular health study: Design and rationaleAnnals of Epidemiology, 1991
- A Unified Approach to Mixed Linear ModelsThe American Statistician, 1991
- Factorial and discriminant validity of the center for epidemiological studies depression (CES-D) scaleJournal of Clinical Psychology, 1986